Cellular plasticity associated with fluctuations in transcriptional programs allows individual
cells in a tumor to adopt heterogeneous differentiation states and switch phenotype during …

Cell-to-cell variability generates subpopulations of drug-tolerant cells that diminish the
efficacy of cancer drugs. Efficacious combination therapies are thus needed to block drug-tolerant …

While efforts to identify microglial subtypes have recently accelerated, the relation of
transcriptomically defined states to function has been largely limited to in silico annotations. Here, …

Dendritic cell (DC)-based immunotherapies have much utility in their ability to prime antigen-specific
adaptive immune responses. However, there does not yet exist a consensus …

The discovery of genetic abnormalities together with the fast pace of drug development has
led to an expanding number of mutation-tailored treatments for human diseases. This …

Resistance due to tumor cell heterogeneity poses a major challenge to the use of targeted
therapies for cancer treatment. Targeted therapies that are designed to block oncogenic …

The Biointerfaces Interlaboratory Committees, the student organization for the Biointerfaces
Institute at the University of Michigan, organized and executed an 8 hour “BioHackathon” on …

Technological advances in generated molecular and cell biological data are transforming
biomedical research. Sequencing, multi-omics and imaging technologies are likely to have …

Dose-response curves are key metrics in pharmacology and biology to assess phenotypic
or molecular actions of bioactive compounds in a quantitative fashion. Yet, it is often unclear …

Most patients with BRAF-mutant metastatic melanoma display remarkable but incomplete
and short-lived responses to inhibitors of the BRAF kinase or the mitogen-activated protein …